Violeta Régnier Galvão

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

James J. Harding, Víctor Moreno, Yung‐Jue Bang et al. · Clinical Cancer Research · 2021 · 155 citations · Full text

Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions

Matthieu Picard, Leyla Pur Özyiğit, Joana Caiado et al. · Journal of Allergy and Clinical Immunology · 2015 · 122 citations

Drug Hypersensitivity, Allergy, Atopic Dermatitis +10

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Matthew D. Hellmann, Nicoletta Bivi, Boris Calderón et al. · Clinical Cancer Research · 2021 · 106 citations · Full text

Basophil Activation Test is a Relevant Biomarker of the Outcome of Rapid Desensitization in Platinum Compounds-Allergy

Pedro Giavina‐Bianchi, Violeta Régnier Galvão, Matthieu Picard et al. · The Journal of Allergy and Clinical Immunology In Practice · 2016 · 83 citations

Asthma, Inflammation, Drug Hypersensitivity +14

A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer

Nuria Kotecki, Perrine Vuagnat, Bert H. O’Neil et al. · Journal of Immunotherapy · 2021 · 31 citations